PBM
OCS icon

Propel Bio Management’s Oculis Holding OCS Stock Holding History

Propel Bio Management’s Portfolio OCS Stock Details OCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-122,223
Closed -$3.28M – 34
2026
Q1 		$3.28M Sell
122,223
-50,616
-29% -$1.34M 2.07% 17
2025
Q4 		$3.45M Buy
+172,839
New +$3.46M 2.95% 13

Other funds holding OCS

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Propel Bio Management's OCS Position: Q2 2026 in Review

Propel Bio Management sold out of Oculis Holding (OCS) in Q2 2026, closing a stake of 122,223 shares — an estimated $3.28M sold.

Propel Bio Management first reported a position in OCS in Q4 2025 and held it in 2 quarters. The position peaked at $3.45M in Q4 2025. 59 funds tracked by Wall St. Rank hold OCS as of Q2 2026.

  • Propel Bio Management reported no remaining Oculis Holding position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 122,223 Oculis Holding shares in Q2 2026, an estimated $3.28M.
  • Propel Bio Management first reported a position in Oculis Holding in Q4 2025 and held it in 2 quarters.
  • Propel Bio Management's Oculis Holding position peaked at $3.45M in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oculis Holding as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.